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Abstract 
Polypharmacy among psychiatric patients is a concerning trend. From 2007-2010, 58.2% 
of women and 41.8% of men reported taking five or more prescription drugs within the last 30 
days (CDC, 2014). Negative outcomes include prescription drug abuse, side effects, interactions, 
treatment failure, patient dissatisfaction, and lack of treatment control. The associated practice 
challenges have led to the following PICOT question. In persons with mental health issues 
receiving care at an outpatient mental health clinic, does engaging in mindfulness practice versus 
no mindfulness practice change polypharmacy use over a 3-month period? The project purpose 
was to evaluate the effectiveness of Insight Timer mobile mindfulness app at helping patients 
self-manage distressing symptoms and reduce polypharmacy. Over three weeks, mental health 
clinic nurse practitioners (NPs) voluntarily recruited patients (n=12) over age 18 using as needed 
prescriptions (PRNs), and agreed to use Insight Timer mobile mindfulness app for adjunct 
symptom management. Consenting participants downloaded the mobile app, and completed a 
brief questionnaire measuring PRN use at the start of app use, and PRN use at their next visit. A 
Wilcoxon signed-rank test indicated a 10-week mindfulness app trial did not significantly lower 
total PRN doses compared with pre-app dosing (Z = -.534, p = .593). Paired t-tests revealed no 
significant change in pre (M = 65.17, SD = 28.64) versus post (M = 67.75, SD = 20.22) OQ45 
life functionality results (t(11)  = -.420, p = .683) (d = .121) as a result of app use. Clinically 
relevant results illustrated 83.33% of participants taking greater than nine PRN doses over the 
study period used the app six times or more in place of medication. High PRN users employed 
the app frequently in place of medication regardless of total PRN doses taken. Practice 
implications and sustainability recommendations include incorporating mobile app use in 
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treatment plans for high PRN users and educating NP’s on the tangible benefits of mindfulness 
apps in reducing polypharmacy and easing symptom distress on an ongoing basis.    
Keywords: mindfulness, mhealth, mobile apps, mobile smart phone, online, RCT, 
behavior change, polypharmacy. 
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Reducing Polypharmacy with Mobile Apps Among Mental Health Patients 
Chapter 1 
            Mental healthcare expenditures have changed in nature and grown significantly since the 
1980’s. Americans spent $186 billion on mental health treatments in 2014 (CDC, 2014).  From 
1986 to 2014, spending on mental health medications increased 19%. During the same time, 
outpatient treatment expenditures increased 11% (CDC, 2014). As more patients have been 
funneled toward outpatient mental health clinics, the share of inpatient and residential spending 
has decreased (CDC, 2014). Trends toward outpatient treatment with a greater focus on 
medication management versus impatient hospitalization show no signs of abating. While cost 
cutting measures have been effective at reducing inpatient stays and associated expenditures, 
medication-based management of complex mental health issues has led to increased prescribing 
resulting in polypharmacy (Shuman-Olivier, Noordsy, & Brunette, 2013). From 2007-2010, 
58.2% of women and 41.8% of men reported taking five or more prescription drugs within the 
last 30 days (CDC, 2014). Valid concerns have surfaced regarding polypharmacy including 
prescription drug abuse, drug interactions, adverse drug events, side effects, and reduction in 
individual functioning (Bry, Chou, Miguel, & Comer, 2017). 
Expanding prescription medication use presents new clinical challenges. Intensive 
inpatient hospitalization is no longer widely available or cost effective.  Psychiatric experts 
struggle with how to provide comprehensive mental health care with shrinking resources, shorter 
appointment times, and limited tool box of therapeutic options.  
Problem and Purpose 
Rescue medications such as benzodiazepines are frequently employed to manage 
distressing symptom exacerbations as first line treatment. Using rescue meds in this fashion 
REDUCING POLYPHARMACY  8 
increases polypharmacy with all its requisite complications and concerns (Bry, Chou, Miguel, & 
Comer, 2017). Large gaps in therapeutic success, patient satisfaction, cost effectiveness, and 
patient empowerment exist (Rathbone, Clarry, & Prescott, 2017). Medication dependence and 
abuse is common (Shuman-Olivier, Noordsy, & Brunette, 2013). Patients are reliant on 
medication versus being aware of symptom triggers thereby removing an opportunity for non-
pharmacologic management. Inclusion of effective, ongoing, and evidenced based therapy in 
treatment plans has been challenging given cost and time constraints in most mental health 
clinics.  
The purpose of this project was to review the problem of polypharmacy as it related to 
national trends, healthcare systems, and clinical outcomes with the goal of implementing a 
technology-based solution to improve mental health treatment, empower patients to recognize 
and self-manage distressing symptoms, and decrease polypharmacy. 
Background and Significance 
Negative outcomes are associated with polypharmacy. Lack of treatment success, patient 
dissatisfaction, poor symptom relief, and lack of control over treatment outcomes have 
snowballed into a concerning clinical practice challenge. Rescue meds are being prescribed as a 
front-line treatment with less than optimal outcomes rather than patient directed, self-
management therapies that reduce the need for additional medication (Zhao, Freeman, & Li, 
2016).  
Cognitive Behavioral Therapy 
Patients living with anxiety, panic, depression, and moodiness are treated in an outpatient 
setting with medication alone or a combination of evidenced based therapy such as Cognitive 
Behavioral Therapy (CBT) (Os et al, 2017). The purpose of CBT is to teach patients to monitor 
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and adjust to distressing cognitive, emotional, and behavioral reactions underlying depression 
and anxiety (Barlow et al, 2014). CBT has four main elements and can be employed in practice 
through the use of the Unified Protocol (Barlow et al, 2014; Bakker, Kazantzis, Rickwood, & 
Rickard, 2016). The Unified Protocol is an individual CBT protocol designed by Barlow et al to 
treat anxiety and anxiety related symptoms. The four elements are: 1) increase present focused 
emotional awareness, 2) improve cognitive flexibility, 3) identify and prevent patterns of 
emotional avoidance and mal-adaptive emotion driven behaviors, and 4) promote exposure 
(Barlow et al, 2014; Bakker, Kazantzis, Rickwood, & Rickard, 2016).  
Innovative Mobile Technology 
 Mental health experts are encouraged that new technologies have the potential to 
transform care compared with standard treatments. Mobile technologies are a promising tool to 
improve patient management, decrease polypharmacy, empower patients through self-efficacy 
and symptom management, enhance patient outcomes, and change future standards of practice 
(Bakker, Kazantzis, Rickwood, & Rickard, 2016; Mistler, Ben-Zeev, Carpenter-Song, Brunette, 
& Friedman, 2017; Zhao, Freeman, & Li, 2016). From a systems perspective, decreasing 
polypharmacy with the use of mobile technologies may reduce the overall healthcare burden, 
prescription drug costs, and improve practice efficiencies on a national, local, and individual 
level (Rathbone & Prescott, 2017). Mobile self-help applications have the potential to curb 
billions of dollars in annual prescription drug costs and minimize decreased productivity losses. 
Evidence supports improved outcomes, symptom relief, and empowerment with the use of 
mobile mindfulness apps (Rathbone, Clarry, & Prescott, 2017). Mobile phone ownership is 
ubiquitous as 95% of Americans own a mobile phone with 77% owning a smart phone (Pew 
Research Center, 2016). Additional research shows lower income families often use smartphones 
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as their only internet access point (Alfano & Beidel, 2014; Pew Research Center, 2016 ; Zhao, 
Freeman, & Li, 2016). 
Internal Evidence 
Information collected in an Arizona mental health clinic provides further internal 
evidence of a practice gap. The Clinical Practice Manager reports approximately 75% of their 
patients take more than one med, with greater than 50% of patients taking at least two meds 
prescribed by clinic NPs. The practice has a mixed payer profile with 40% Medicare/Medicaid 
patients, 55% private insurance, and 5% self-paying patients.  Therapists and NPs here treat a 
significant number of patients living with anxiety, panic, and elevated stress levels as primary or 
secondary mental health diagnosis. Rescue medications such as lorazepam, alprazolam, or 
hydroxyzine are first line treatments. Providers prefer to follow clinical practice guidelines 
limiting the number of medications, particularly rescue medications when possible while 
encouraging non-pharmacologic coping behaviors. The clinic provides on-site licensed therapists 
as well as a professionally led exercise program and nutritional coaching in support of this effort. 
Research shows increased patient engagement in positive coping behaviors improves treatment 
outcomes (Hartin et al, 2016). Presumably, patient satisfaction levels would rise accordingly. 
While many patients report symptom relief, taking additional medication leads to added side 
effects and complications. Multiple medications are expensive for the patient and the healthcare 
system. For these reasons, polypharmacy is a challenge that needs to be addressed.  
PICOT 
The background and significance of increased polypharmacy as well as the identified 
problem and practice gap lead to the following PICOT question. In persons with mental health 
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issues receiving care at an outpatient mental health clinic, does engaging in mindfulness practice 
versus no mindfulness practice change polypharmacy use over a 3 month period? 
Exhaustive Search Strategy 
An exhaustive search to extract the highest quality research from PubMed, PsycINFO, 
CINHAL, Science Direct, and Academic Search Premier extends from the PICOT question. 
Searches included the terms “mobile,” “smartphone,” “CBT,” “mindfulness,” “polypharmacy,” 
“anxiety,” “mHealth,” and “RCT.” Inclusion criteria were randomized controlled trials within the 
last 5 years, mobile technology or on-line intervention for improvement in polypharmacy or 
symptom management, mindfulness-based, and designed for clinical application with mental 
health patients. 
The strategy is detailed as follows. A search of PubMed Central yielded 753 studies with 
the terms mobile smartphone AND CBT AND mindfulness AND anxiety AND RCT. This was 
narrowed to 59 studies with using AND versus OR in search parameters, and filtering results to 
the last five years. Additionally, the first search phrase was changed from mobile AND 
smartphone to mobile smartphone (Appendix A). Three relevant studies in the evaluation table 
were included from this search (Appendix F). A search of PsycINFO with terms anxiety AND 
mindfulness AND RCT AND mobile app yielded zero results. Changing the terms to anxiety 
AND mindfulness AND RCT OR mobile app resulted in 32 studies. Additional limiters included 
English language and peer reviewed (Appendix B). One relevant study was included in the 
evaluation table (Appendix F). CINHAL was searched using a variety of terms including 
smartphone, mobile, app, mindfulness, polypharmacy, self-help, and mhealth. Mindfulness AND 
mhealth returned one relevant result (Appendix C). The search was further expanded to 46 
results by changing search terms to mobile apps AND behavior change, but no relevant studies 
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were found. OR and AND were used as links in all search permutations. Using all previous 
searches linked with OR yielded 12 results.  One relevant study is included (Appendix F). 
Science Direct was searched using the terms mindfulness AND online AND RCT in article titles. 
Four results were returned (Appendix D). One study was evaluated and selected (Appendix F). A 
search of Academic Search Premier using the terms mobile apps AND self-help yielded 100 
results. The search was further refined with the filter full text available providing 43 results 
(Appendix E). One relevant study was selected from these results (Appendix F). Two remaining 
studies were hand searched (Appendix F).  
Critical Appraisal and Synthesis 
The strength of available evidence for effectiveness of mobile mindfulness apps at 
eliciting individual behavior change is moderate (Appendix G).  A number of randomized 
controlled trials exist but are of somewhat limited quality as attrition rates and sample sizes are 
not ideal. Populations are relatively heterogenic, ranging from general non-clinical participants 
to purposefully self-selected samples. Self-selection is expected and desired because the primary 
goal of mindfulness app use is decreased medication use through improved self-efficacy. Mean 
ages and populations in the studies selected are appropriate for the outpatient population of 
interest as all studies were limited to adults over 18 years of age and included willing 
participants. Reliability across all studies ranges from reliable to somewhat reliable. Most 
commercially available apps are developed for profit in some way. Bias in several studies exists 
to the extent that researchers are involved in app development or have similar apps in the open 
marketplace. Interestingly, two studies disclosing this bias reported the weakest overall evidence 
for symptom improvement with mobile apps. Similar conclusions exist across studies in 
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symptom improvement, user behavior changes, and the value of adjunctive technology-based 
mindfulness therapy.  
Conclusions/Discussion 
Mobile application technology is evolving and developing daily. The pace of research 
simply cannot keep up with development. Research on mobile apps with specific clear-cut 
guidelines for use and outcome measurements was not located. Extrapolating evidence from the 
best available studies supports the use of mindfulness-based therapies both in-person and via 
mobile apps and could be generalized to an outpatient mental health setting. Practicing 
mindfulness was shown to positively impact various vital signs such as heart rate and blood 
pressure as well as psychological factors like mood, depression, and anxiety. Mindfulness-based 
therapies also impacted patient behaviors such as decreasing psychomotor agitation, improve 
coping, and create synergistic effects with adjunct anti-depressant medications. Mindfulness, 
regardless of delivery method, was shown across multiple studies to improve coping mechanisms 
as well as improve depressive symptoms. Evidence supports improved therapeutic engagement 
via mobile mindfulness apps increases self-efficacy and provides immediate relief from 
symptoms such as anxiety, agitation, depression, and stress.  
Based on the evidence at hand, incorporating a protocol for mobile mindfulness apps in 
an outpatient setting to decrease symptoms of anxiety, depression, agitation, and stress might be 
effective at reducing these symptoms in patients. A decrease in undesirable symptoms could 
reduce use of rescue medications achieving a primary goal of the outpatient facility. Piloting the 
use of mobile mindfulness apps is warranted. 
 
 
REDUCING POLYPHARMACY  14 
Chapter 2 
Contribution of theory to utility of the evidence 
Albert Bandura’s Theory of Self Efficacy (1977) is the framework on which this project 
and research is based (Appendix H).  One of the central themes of self-efficacy is the 
understanding a patient who engages in a treatment or intervention will further begin to self-
promote and more fully utilize the intervention over time as individual engagement increases 
(Bandura, 1977). The same foundation of self-efficacy is present throughout most of the selected 
research. Examining the research question at hand, one can see how polypharmacy may be 
reduced with mobile technology, but even more so with increased self-efficacy and a desire to 
use mobile apps as a vehicle for improved coping and reducing personal medication usage. 
Evidence Based Practice Model 
Implementing an evidence-based practice change works congruently with the nursing 
process; assess, diagnose, plan, implement, and evaluate. As such, a comprehensive approach to 
internal needs analysis, evidence gathering, critical appraisal, planning and implementation is 
necessary. The Iowa Model of Evidence-Based Practice to Promote Quality Care was the 
working model used to guide research and decision making (Appendix I; Rycroft-Malone & 
Bucknall, 2010).   
Both problem and knowledge focused triggers have led to an understanding that a NP led 
polypharmacy reduction effort is necessary. NPs at a local community health clinic have noticed 
an unfortunate increase in polypharmacy across their patient population. Recommendations for 
minimizing the use of controlled medications are becoming more stringent as the negative effects 
of polypharmacy is increasingly under the microscope (Kouladjian, Gnjidic, Chen, Mangoni, & 
Hilmer, 2014). The organization’s philosophy of care advises limiting unnecessary medication 
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and supports including evidenced based non-pharmacologic treatment adjuncts in an effort to 
provide holistic patient centered interventions. The company’s CEO has tasked NPs with 
implementing efficiencies and practice improvements through technology. The clinical 
management created a team to meet this organizational priority yielding the research and analysis 
presented here.  
Sufficient evidence existed to pilot a practice change to reduce polypharmacy and 
encourage greater patient autonomy and self-efficacy through mobile apps. Goals of a pilot 
program included reducing total polypharmacy individually in patients identified as utilizing 
rescue medications, minimizing the number of prescriptions refilled as a comparative percentage 
from baseline, and eliciting patient feedback on the use of mobile apps as a treatment adjunct and 
effectiveness compared with rescue medications. Guidelines were developed below for patient 
inclusion in the pilot mobile app polypharmacy reduction program. Methods, outcome measures, 
data analysis and results are presented below determining effectiveness and sustainability 
recommendations for a company-wide roll out.   
Project Purpose 
In order to combat polypharmacy at a local community mental health clinic, the research 
team selected a mobile mindfulness meditation app called Insight Timer to help patients manage 
distressing symptoms and decrease polypharmacy. The team chose Insight Timer because the app 
allowed for individual accommodation for time constraints, diagnosis, and/or target symptoms 
treatment.  The project purpose was to evaluate the effectiveness of Insight Timer Mobile App at 
helping patients self-manage distressing symptoms and reduce PRN medication use. Patients 
would benefit from increased mindfulness, treatment control, and positive coping behaviors 
related to managing distressing symptoms with Insight Timer. The clinic and NPs would benefit 
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by including an inexpensive, easily accessible, technology-based intervention in their therapeutic 
repertoire. 
Methods 
Recruitment, protection of human subjects, and patient privacy  
The study population included adults identified by the NPs and clinical manager who 
were using PRN prescriptions and were amenable to using Insight Timer mobile mindfulness app 
as an adjunct non-pharmacologic symptom management tool. NPs provided the patient with a 
recruitment flyer. If they chose to participate, they met with the co-investigator regarding 
expectations of the study and consented in writing after all questions were answered. The 
research team instituted the following inclusion and exclusion criteria. The primary inclusion 
requirements were: 1) patients had to be age 18 years or older, 2) had to own a smart phone; 3) 
had to be taking at least one PRN med; 4) and were agreeable to using Insight Timer mobile 
mindfulness app as part of their current treatment. Minors, adults who were unable to consent, 
prisoners, and pregnant women were excluded from participation. Race and citizenship status 
were not relevant to the study and were not tracked. All participants were English speaking. 
After obtaining IRB approval a variety of protections were put in place to ensure human 
rights were maintained during this project (Appendix J). First, patients participated in an 
informed consent process. Participants consented in writing after meeting with the co-primary 
investigator to learn about the project. Completing beginning surveys and downloading Insight 
Timer was considered consent to participate. Second, participants were provided as long as 
needed to review consent and ask questions related to the study prior to agreeing to participate. 
Finally, risks and benefits were reviewed. Risks were noted to be no greater than those 
associated with everyday types of activity. If symptoms worsened or a participant felt unsafe 
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they were informed they could schedule and emergency appointment or be referred to the 
emergency department. Benefits of participation were also discussed such as research indicating 
mindfulness therapies have been shown to result in increases in positive coping behaviors which 
may include decreasing use of PRNs when possible. The primary benefit of the pilot program for 
participants is to improve mindfulness, individual empowerment over symptoms, and non-
pharmacologic symptom management by using a mobile mindfulness application. 
Privacy measures for participant data were also implemented. The co-primary 
investigator had data access and was responsible for data security. The questionnaires were 
stored in a locked file cabinet at the facility. Participants developed their own unique 
identification code at the initial meeting. This code was not connected to their name or other 
personal identifying information. A master list of participants with their ID code was stored on a 
password protected computer at the facility. Data was destroyed after analysis was completed.  
Setting, Culture, and Innovative Leadership 
The project setting was a local community mental health clinic in Arizona. The patient 
population at this clinic is general mental health patients with a variety of common psychiatric 
diagnosis. Approximately five or six NPs provide medication management and multiple 
therapists and counselors provide therapy services. Nutritional coaching and personal training 
services are also on site. Services are available to adults over the age of 18. The payer mix is 
varied with 40% Medicare/Medicaid patients, 55% private insurance, and 5% self-pay patients.  
The project site is unique. The philosophy of the CEO and providers is to deliver patient-
centered, individually tailored, and multifaceted psychiatric services to their patients. Clinic staff 
strive to exceed expectations by providing a full complement of mind-body services to assist 
patients on their road to mental health and wellness. This philosophy is evidenced by the 
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incorporation of therapists specializing in modalities such as Eye Movement Desensitization and 
Reprocessing (EMDR), Cognitive Behavioral Therapy (CBT), and Dialectical Behavioral 
Therapy (DBT), as well as counselors, nutritional coaches, personal trainers, and a non-
pharmacologic pain management program in addition to the NP provided medication and therapy 
options. Each provider individualizes care through a unique lens. They are well supported in 
their autonomy to deliver the best evidence-based treatments possible. 
The CEO supports and values innovative use of technology and efficiencies across all 
service lines. This project grew out of a directive from him to have the NP staff incorporate 
technology more robustly into their work flows. In addition to psychiatric services, this company 
offers crisis services, trauma services, and disaster relief. The executive leadership has a clear 
vision of delivering an exceptional health and wellness product and is nimble in their response to 
changing complexities in healthcare delivery. 
Collaborators and Research Team Members 
The co-investigator worked with the NPs, Clinical Manager, and medical assistants to 
enroll the patients in the project. Site employees were helpful assisting the co-investigator meet 
the goals of recruitment and providing adequate space for patient meetings and consent. The NPs 
and Clinical Manager were engaged in identifying patients that could benefit from the Insight 
Timer intervention. The medical assistants (MAs) were invaluable in making sure there was 
adequate time scheduled for meeting and completing study questionnaires. 
Intervention Process 
Following IRB approval, a 10-week evidence-based practice (EBP) project was 
implemented at an Arizona outpatient mental health clinic using Insight Timer mobile app. Over 
three weeks, NP’s recruited patients (n=12) over age 18 for participation. The co-investigator 
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worked with the NPs and MAs to enroll and educate the patients on the purpose of the mobile 
app project, their role in reporting information on their next visit, and assist in downloading and 
brief instruction of Insight Timer to use as a mindfulness improvement tool until their next visit. 
Consenting participants downloaded the mobile app, and completed a brief questionnaire 
measuring PRN use at the start of app use (Appendix K), and PRN use at their next visit 
(Appendix L). The 45-item Outcomes Questionnaire 45.2 (OQ-45.2) was administered 
simultaneously to measure total score (TS) as well as 3 functional domains; symptom distress 
(SD), interpersonal relations (IR), and social role (SR) before and after starting the app (Lambert 
et al, 2013) (Appendix M). 
Outcome Measures 
Outcome measurements were taken at the participant’s next visit (within 10 weeks). 
These included a post-intervention demographic questionnaire and post OQ-45.2 assessment. 
Additional qualitative data including personal satisfaction with Insight Timer, reasons for non-
completion or switching to a different app, and general self-reported experiences with app use 
were also analyzed. Quantitative outcome measures included number of PRN doses taken before 
and after Insight Timer use. The number of times the app was used in place of PRN medication 
was also measured. 
Validity and Reliability 
The OQ-45.2 Inventory is a valid and reliable (r= .94) 45-item questionnaire. The OQ-
45.2 measures total score (TS) as well as 3 functional domains; symptom distress (SD), 
interpersonal relations (IR), and social role (SR) before and after starting the app. Cronbach’s 
alphas for each domain and TS are: SD (.93), IR (.78), SR (.70), and TS (.94). Correlations 
indicate strong support for the validity of the OQ-45.2 TS and SD domain (Lambert et al, 2013).  
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Data Collection, Analysis, and Budget 
             The co-researcher coded pre and post intervention questionnaires and the OQ-45.2 
instrument. Over 10-weeks, the research team collected data at the outpatient clinic with care to 
maintain data security and patient privacy according to the recruitment, protection of human 
subjects, and patient privacy protocol previously noted. Data was then analyzed using IBM SPSS 
Statistics 23. The project was funded by the co-investigator. Costs were minimal; less than $50 
for photocopy and printing services. Office space to conduct participant meetings was provided 
free of charge by the outpatient clinic.  
Methodology 
Descriptive statistics were used to describe the sample and outcome variables. Mean 
doses of PRNs pre and post intervention did not meet the assumptions of the normal distribution 
of scores after running tests for normalcy, therefore the non-parametric Wilcoxon signed rank 
test was performed. Paired t-tests were used to analyze pre and post intervention OQ-45.2 data. 
The critical value was set at p <.05 and a two tailed test was run.  
Results 
     Twelve participants (11= female, 1= male), with an average age of 38 completed the 
study (M=38, SD=13.08). Ages ranged from 20 to 62 years of age. A Wilcoxon signed rank test 
revealed a 10-week mindfulness app trial did not significantly lower average post app PRN doses 
compared with pre-app dosing (Z = -.534, p = .693).  A paired t-test was calculated to compare 
mean pre-app use 65.16 (M=65.16, SD= 28.64) versus post app use 67.75 (M=67.75, SD= 20.22) 
OQ45.2 total life functioning scores as well as pre versus post app use scores for the three 
instrument domains. Average pre-app life functioning total scores ranged from 29 to 115 while 
average post app life functioning total scores ranged from 29 to 96. Pre mean app use scores for 
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Symptom Distress (M=39.12, SD=19.75), Social Role (M=10.08, SD=5.47), and Interpersonal 
Relations (M=15.67, SD=7.08) were compared with post app use scores for each domain SD 
(M=44.67, SD=13.23), SR (M=8.92, SD=3.99), IR (M=14.14, SD=7.58). No significant change 
in OQ45.2 life functioning total scores was seen pre (M= 65.17, SD = 28.64) versus post (M= 
67.75, SD= 20.22) app use. (t(11)= -.420, p>.05). (d= .121). Similarly, no significant changes 
were seen in pre vs post domain scores.  
        Clinically significant results included 83.3% of patients taking greater than nine PRN doses 
over the study period used the app six times or more in place of medication. This finding 
illustrated high PRN users employed the app frequently in place of medication.  
        Unintended findings included a patient report of app use as a replacement for alcohol in the 
evenings. A PTSD patient reported app use for AM focus and concentration versus sleep hygiene 
and reduced propranolol PRNs. Another patient reported anxiety exacerbation, increasing both 
PRN lorazepam use and app sessions. 
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Chapter 3 
Discussion and Practice Implications 
              High PRN users employed the mobile mindfulness app frequently in place of 
medication potentially out of need and/or desire to reduce PRN use.  Active patient directed 
mindfulness app use suggests increased treatment engagement illustrating Self-Efficacy Theory 
at work on an individualized basis. Incidental findings such as utilizing Insight Timer for 
additional mindfulness needs like reducing nightly alcohol intake; or treating additional 
distressing symptoms not initially identified as the primary focus of app use further support the 
use of patient directed mindfulness therapies across a wide range of diagnosis.  Increased levels 
of app use in high PRN users support conclusions these participants derived substantial benefits 
from Insight Timer possibly because symptoms were particularly distressing. High PRN users 
are high need as evidenced by greater than 80% using the app regularly in place of medication.  
 This project is not without limitations. A longer study period, such as six months or a year 
with multiple points of patient contact might yield statistically significant findings. Additional 
patient experience questions on the demographic questionnaires may be useful as well. For 
example, it would be helpful to know how the patients perceive the severity of their symptoms, 
and if app use was more effective for mild, moderate, or severe symptoms. The project sample 
size is limited as is consistent with most studies of this kind. A larger sample might reveal  
results representative of broader mental health treatment experiences. Additionally, a two group 
study design with an app use group and a control group may provide more concrete conclusions. 
Recommendations and Sustainability 
               Findings from this project indicate app use appears particularly beneficial for high need 
patients. Treatment plans of high PRN users should include mindfulness apps as first line non-
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pharmacologic therapy to reduce reliance on rescue medications where appropriate. Identifying 
patients who are receptive to mindfulness therapies as an adjunct treatment modality is useful for 
improving treatment engagement. Educating future clinic NP’s on the tangible benefits of 
mindfulness apps in reducing polypharmacy and easing symptom distress will encourage 
implementation of this intervention on an ongoing basis.   
Conclusion 
             Use of mobile mindfulness apps results in positive behavior changes and increased 
treatment engagement as evidence by the results of this project. Implementing a patient directed 
mindfulness app intervention has the potential to reduce individual PRN use well as overall 
polypharmacy. Greater patient self-efficacy and participation in self-care may lead to reduced 
depression and anxiety scores over time. Further research is needed on efficacy of mindfulness 
apps on polypharmacy reduction in clinical practice and among broader mental health 
populations. Mindfulness app use in this clinical setting illustrated the potential of technology to 
improve measurable patient outcomes, decrease PRN use, and advance the overarching goal of 
improving mental health treatments.  
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practice, 
rumination and 
clinical outcome 
in mindfulness-
based 
treatment 
 
Funding: 
NIMH 
 
Conflict/bias: 
None 
 
Country: 
Health Belief 
Model 
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Determine 
whether 
rumination & 
distraction 
were affected 
and/or 
decreased 
with 
mindfulness, 
if so, does 
mindfulness 
type affect 
depressive 
symptoms   
Mixed 
methods 
 
 
Correlate and 
Compare 2 
data sets from 
2 previous 
RCT’s 
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Age 18-65 
 
Mean 44.1 
 
60% female 
 
83.3% white 
 
Experience 
remission of 
depression 
as measured 
by 50% 
decrease in 
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AND 
MBCT grp n=18 
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Structure 
Clinical 
Interview for 
DSM-IV 
 
HRSD-21 
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IBM SPSS 
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Bootstrappin
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Multiple 
regression 
analysis 
No 
significant 
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between 
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and 
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beneficial but 
not as much 
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Level 1 
 
First study 
examining 
specific forms 
MDF and 
symptom 
alleviation 
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beneficial but not 
for depression 
symptoms 
 
MDF effective 
for depression 
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of blended tx 
of 4 in person 
n= 93 
 
Age 18 or > 
 
Consumed 
none or 
fixed dose of 
medication 
for 
depression 
and anxiety 
IV- Smart app 
and in person 
blended n = 46 
 
DV- In-person 
only tx n = 47 
 
 
Primary = BDI-
II 
 
Secondary = 
PHQ-9, BAI, 
QOLI 
 
Clinician 
administered: 
MINI 
 
IBM SPSS 
20 
 
Indept. 
Samples t-
test 
 
Chi-square 
 
Cohen’s d 
n=93 
16 (25.8%) 
did not 
submit self-
report 
measures 
 
88 completed 
all in person 
tx. 
 
Level II 
 
Small sample 
size, bias, 
attrition >25% 
 
Blended tx 
almost as 
effective as full 
in-person, more 
efficient 
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Funding: 
SRC, ECSFP, 
Wemind 
Psykiatari 
Stockholm 
 
Conflict/bias: 
Ly, K.H. 
develops 
version of app 
for open market 
 
Country: 
Netherlands 
 
100% in-
person tx. 
sessions and 
smart app vs 
full in person 
behavioral tx 
 
Depression 
diagnosed 
via DSM-IV 
 
> 5 on PHQ-
9 scale 
 
No comorbid 
psychiatric 
diagnosis, 
i.e, bipolar 
 
No severe 
alcohol 
problems >8 
on AUDIT 
test 
 
No medical 
problems 
requiring 
treatment 
 
No 
DTS per 
MINI 
Credibility & 
working 
alliance 
measurement: 
C-Scale 
Avg. 
therapist time 
blended = 
321 min 
In-person 
=600min 
47% less 
 
BDI-II scores 
dropped 
12.75 pts 
overall. No 
significant 
difference 
between 
groups 
 
Blended tx 
almost as 
effective as 
full in-
person, more 
efficient 
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Ly, K. et al. 
2014 
 
Behavioural 
activation 
versus 
mindfulness-
based guided 
self-help 
treatment 
administered 
through a 
smartphone 
application: A 
randomized 
controlled trial. 
 
Funding: 
SRC 
 
Conflict/bias: 
Ly, K. has a 
related version 
of the app on 
the open market 
 
Country: 
Sweden 
Self-Efficacy 
 
Purpose: 
Compare 
effectiveness 
of CBT vs 
MDF smart 
phone app 
Parallel 
randomized 
control, open, 
trial 
 
2 groups 
randomized 
to CBT app 
group and 
MDF app 
group. 
Results 
reported and 
examined 
after 8 weeks. 
n=81 
 
Purposeful 
self-
selection via 
Swedish 
mass media 
 
Mean 
age=36 
 
Confirmed 
diagnosis of 
major 
depression 
 
>18 yrs old, 
PHQ-9>5, 
unchanged 
med doses 
over last 
month, no 
concurrent 
psych tx., no 
comorbid 
psych 
diagnosis, no 
medical 
problems 
needing tx., 
no severe 
alcohol 
prob., no 
DTS 
IV=MDF app 
n=40 
IV=BA app n=41 
BDI-II 
 
PHQ-9 
 
BAI 
 
QOLI 
 
AAQ-II 
 
MINI 
IBM SPSS 
20 
 
Independent 
t-test 
 
Chi-square 
 
Mixed 
effects 
models 
 
Power 
analysis 
(89%) 
 
Cohen’s d 
15.9% AR 
 
MDF more 
effective in 
less severe 
initial 
depression 
 
Recovery 
rates similar 
across both 
BA and MDF 
groups 
 
82.4% BA 
less severe 
sympt. 
recovered  vs 
92.3% MDF 
less severe 
sympt. 
Level II 
 
Underpowered, 
recruited via 
mass media, 
generalizable to 
clinic??, most 
participants 
college educated 
 
First completely 
app only 
delivered therapy 
 
MDF more 
effective in less 
severe initial 
depression 
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Mantani, A. et 
al. 
2017 
 
Smartphone 
cognitive 
behavioral 
therapy as an 
adjunct to 
pharmacotherap
y for refractory 
depression: 
Randomized 
controlled trial. 
 
Funding: 
JMHLW, 
JFNMH, 
received 
donations from 
major drug 
companies 
including Eli 
Lilly, GSK, 
Janssen, and 
Pfizer 
 
Conflict/bias: 
Self-Efficacy 
 
Purpose: 
Evaluate 
effectiveness 
of app in 
anti-
depressant 
treatment 
resistant 
depression 
RCT 
 
Method: 
Evaluate 
effectiveness 
of app in 
medication 
change group 
versus 
medication 
change and 
app group in 
treatment 
resistant 
depression. 
n=164 
 
20 Japanese 
psychiatric 
clinics 
 
Primary 
diagnosis of 
depression 
 
Anti-
depressant 
refractory 
after 1 or 
more anti-
depressants 
at adequate 
dose for  > 4 
weeks 
 
Score >10 
on BDI-II 
 
Randomized 
to med 
switch alone 
vs med 
IV= med change 
and app CBT n= 
81 
 
DV= med change 
alone n= 83 
Interview 
 
PHQ-9, BDI-II, 
FIBSER 
SAS version 
9.4 
 
Linear 
mixed model 
with a 
95%CI 
Med switch 
& App group 
n=57 scored  
1.77 pts 
lower on 
PHQ-9, 3.2 
pts lower on 
BDI-II, 0.75 
pts lower on 
FISBER. 
95% CI 
 
Measurable 
results up to 
week 17 
Level  
I 
 
Bias moderate 
 
Results specific  
to Kokoro app 
 
Improved 
depression in 
multiple 
assessment scales 
short term and at 
17 wk follow up. 
 
Apps work as 
adjunctive 
treatment in anti-
depressant 
treatment 
resistant 
depressed 
persons. 
 
Short and long 
term benefits 
seen at 17wk 
follow up 
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Many authors 
receive drug 
company 
funding, two 
authors 
developed 
Kokoro app 
 
Country: Japan 
switch and 
app CBT 
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Meinlschmidt, 
G. et al. 
2016 
 
Smartphone-
based 
psychotherapeut
ic micro-
interventions to 
improve mood 
in a real-world 
setting 
 
Funding: 
University of 
Surrey and 
Canterbury 
Christ Church 
University 
Self-Efficacy 
 
Purpose: To 
test 
effectiveness 
of 
smartphone 
MDF and 
CBT apps 
and their 
effect on 
mood in a 
healthy, non-
clinical,  
population 
Mixed 
methods 
study 
 
Men selected 
from a larger 
study group 
used smart 
apps and 
were exposed 
to multiple 
different 
types of 
mindfulness, 
transcendenta
l meditation, 
and CBT 
therapies and 
reported 
n=27 
 
All males, 
Age 18-65, 
Right 
handed, not 
color-blind, 
no hx of 
cardiac, 
neuro, 
mental 
health 
disorders, 
English 
speaking, 
smart phone 
familiar 
 
 
IVa= 
psychotherapeutic 
technique 
IVb=viscerosenso
ry attention 
IVc=other 
DV=no 
intervention 
MMSQ R Project for 
Statistical 
Computing 
 
Two-tailed t-
test 
Mood 
improved pre 
to post micro 
intervention. 
p=0.022 
 
Increase in 
mood across 
days not 
significant. 
p=0.276 
 
Subjects 
calmer pre-
post 
intervention, 
but not across 
days 
Level III 
 
Small SS, all 
male, highly 
selected 
candidates 
 
App use 
positively affects 
mood and level 
of relaxation 
immediately 
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Conflict/bias: 
None 
 
Country: 
S. Korea 
mood at start 
of day and 
end of day. 
Purposeful 
self-
selection 
from broader 
study 
participant 
Os, J. et al. 
2017 
 
The experience 
sampling 
method as an 
mHealth tool to 
support self-
monitoring, 
self-insight, and 
personalized 
health care in 
clinical practice. 
 
Funding: 
NORSC, 
ECSFP, 
Weijerhorst 
Stichting 
 
Conflict/bias: 
none 
 
Country: 
Netherlands 
Self-Efficacy 
 
Purpose: 
To examine 
large scale 
patient 
reported 
experiences 
to improve 
app 
personalizati
on and 
effectiveness  
Large Mixed 
methods 
qualitative 
and 
quantitative  
 
Method: 
Review & 
analysis of  
auto-
correlation of 
experience 
sampling 
methodology 
applied via 
smart apps to 
support 
greater app 
personalizatio
n and 
efficacy in 
clinical 
practice 
Large 
university 
maintained 
database 
with 
comparable 
experiencing 
monitoring 
lists 
 
Controls n = 
276, 
Healthy 
twins n = 
601, relative 
of  pt with 
psychotic 
disorder n = 
178, pts with 
psychotic 
disorder n = 
293, 
depression n 
= 115, 
residual 
depression n 
= 129, risk 
for psychotic 
Report of Feeling 
Down 
Controls n = 251, 
residual 
depression n=n 
129, depression n 
= 45 
 
Report of feeling 
down via location 
Controls n = 251, 
residual 
depression n=n 
129, depression n 
= 45 
 
Report of feeling 
suspicious 
paranoia 
Controls n = 212, 
residual 
depression n=n 
129, psychotic 
disorder n = 293 
 
Report of Positive 
effect vs no effect 
after 6 weeks of 
Self-report 
beep counter 
 
Auto-
correlation over 
successive lags 
of ESM 
 
Interview 
 
HAM-D 
Mean of 
self-report 
(10 random 
measuremen
ts per day 
over 6 days) 
Self-
monitoring 
increased 
resiliency and 
decreased 
low mood, 
paranoia 
 
Self- 
monitoring 
increased 
personalizatio
n in psych 
med dosing, 
accuracy in 
dosing 
Level I 
 
Large SS, 
Generalizable 
across multiple 
populations 
 
Self-monitoring 
data can be used 
to improve med 
prescribing, 
monitor effect, 
improve dosing 
and accuracy 
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disorder n = 
106 
 
initiation of 
imipramine in 26 
pts 
50% reduction in 
HAMD at 6 wks 
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Roemer, L. et 
al. 
2008 
 
Efficacy of an 
acceptance-
based behavior 
therapy for 
generalized 
anxiety 
disorder: 
Evaluation in a 
randomized 
controlled trial 
 
Funding: NIMH 
 
Conflict/bias: 
Self-Efficacy 
 
Purpose: 
Decrease 
anxiety and 
avoidance in 
anxiety pts. 
via in-person 
exposure 
therapy and 
mindfulness 
training. 
RCT 
 
Method: 
16 in-person 
sessions 
focused on 
exposure, 
habitual 
anxious 
responding, 
mindfulness 
and self-
monitoring 
n=31 
 
25 
participants 
completed 
study 
 
Age 18>  
Primary 
diagnosis 
GAD 
referred by 
provider 
 
Excluded: 
bipolar, 
substance 
abuse, 
IV=treatment 
group n=16 
DV=wait list 
group n=15 
 
 
ADIS-IV 
 
PSWQ 
 
DASS 
 
BDI-II 
 
QOLI 
 
AAQ 
 
MAAS 
Hierarchical 
Linear and 
Nonlinear 
Modeling 
software 
 
Multilevel 
regression 
analysis 
 
Means 
 
Standard 
errors 
 
Between-
groups t-test 
ABBT 
therapy 
decreased 
anxiety in all 
measurement 
instruments 
 
Positive 
anxiety 
results seen at 
9 mos. 
Level I 
 
AR= 22%, 
Small SS, 
customized 
ABBT, 
underpowered 
 
ABBT  decreased 
anxiety in all 
measures 
 
Positive anxiety 
results seen at 9 
mos. 
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None 
 
Country: USA 
psychotic 
disorders, 
DTS 
Mindfulness is 
core tenet of 
ABBT 
Running head: REDUCING POLYPHARMACY  45 
ABBT-Acceptance Based Behavior Therapy, IR-Immediate Response, SR – Sustained Response at follow-up, IFB- Individual Functional 
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Table 2  
Synthesis Table 
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Year 2015 2013 2016 2014 n.d. 2013 2017 2016 2017 2008 
LOE II II I I II II I III I I 
Design RCT RCT RCT MM RCT RCT RCT MM MM RCT 
Mean Age 38.1 24.7 40-60 44.1 30.6 36 40.2 24.3 N/A 33.9 
Attrition 0%** 46% 0% N/A 25.8 21% 2% N/A N/A 22% 
Bias None None None None *** *** M M None None 
# of participants 56 104 144 32 93 81 164 27 1592 31 
 Reliability  MR MR R R MAR MR R MR R R 
 BA&IPMDFT     X      
In
te
rv
en
tio
ns
 
ABBT          X 
ET          X 
In-person MBT*    X X     X 
MDF/CBT App X  X  X X X    
Education   X       X 
On-line MBT  X         
Self-lead MBT     X       
Medication Chng       X    
 Stress/ PS ↓ ↓         
 Coping/Mood  ↑       ↑   
 HR and/or BP ↓  ↓        
M
aj
or
 fi
nd
in
gs
  
Anxiety  ↓        ↓ 
Depression  ↓ ↓ ↓*  ↓ ↓    
Mindfulness  ↑  ↑*      ↑ 
QOL   ↑         
Agitation ↓       ↓  ↓ 
Efficiency     ↑    ↑  
IFB   ↑       ↑ 
IR ↓  ↑    ↑ ↑  ↑ 
SR   ↑    ↑  ↑ ↑ 
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